Oxidized fatty acids: A potential pathogenic link between fatty liver and type 2 diabetes in obese adolescents?

Antioxidants and Redox Signaling

Volumn 20, Issue 2, 2014, Pages 383-389

  Santoro, Nicola ^a   Caprio, Sonia ^a   Giannini, Cosimo ^a   Kim, Grace ^a   Kursawe, Romy ^a   Pierpont, Bridget ^a   Shaw, Melissa M ^a   Feldstein, Ariel E ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 13 HYDROXY OCTADECADIENOIC ACID; 13 OXO OCTADECADIENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; 9 HYDROXY OCTADECADIENOIC ACID; 9 OXO OCTADECADIENOIC ACID; ARACHIDONIC ACID; BIOLOGICAL MARKER; CASPASE; CYTOKERATIN 18 FRAGMENT; FATTY ACID DERIVATIVE; GLUCOSE; HYDROXYICOSATETRAENOIC ACID; INSULIN; LINOLEIC ACID; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT DISEASE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; FAT CONTENT; FATTY ACID OXIDATION; FEMALE; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FATTY LIVER; FEMALE; GLUCOSE; HUMANS; INSULIN; LIPASE; LIPID METABOLISM; LIVER; MALE; MEMBRANE PROTEINS; OBESITY; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84891785074     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5466     Document Type: Review

References (9)

1. DAdamo E, Santoro N, and Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Pediatr Clin North Am 58: 1241-1255, 2011.
2. Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, Zhang R, McIntyre TM, and Hazen SL. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 51: 3046-3054, 2010.
3. Krey G, Braissant O, LHorset F, Kalkhoven E, Perroud M, Parker MG, and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-Activated receptors by coactivatordependent receptor ligand assay. Mol Endocrinol 11: 779-791, 1997.
4. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, and Nadler JL.12-Lipoxygenase products reduce insulin secretion and {beta}-cell viability in human islets. J Clin Endocrinol Metab 95: 887-893, 2010.
5. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, Contos MJ, Sterling RK, Fuchs M, Zhou H, Watkins SM, and Sanyal AJ. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50: 1827-1838, 2009.
6. Ramsden CE, Ringel A, Feldstein AE, Taha AY, MacIntosh BA, Hibbeln JR, Majchrzak-Hong SF, et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids 87: 135-141, 2012.
7. Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, and Caprio S. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One 7: e37827, 2012.
8. Wei D, Li J, Shen M, Jia W, Chen N, Chen T, Su D, Tian H, Zheng S, Dai Y, and Zhao A. Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic beta-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes 59: 471-478, 2010.
9. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, and McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 54: 1610-1619, 2011.